Mar 19 |
Crinetics Stock Jets 16% Higher, Reversing A Three-Week Decline On Its Phase 3 Win
|
Mar 19 |
Crinetics gains as late-stage trial for lead drug succeeds
|
Mar 19 |
UPDATE 2-Crinetics' hormonal disorder drug succeeds in late-stage study
|
Mar 19 |
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
|
Mar 12 |
Crinetics reports encouraging Phase 2 data for carcinoid syndrome drug
|
Mar 12 |
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
|
Mar 11 |
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Mar 6 |
Citi starts Crinetics at buy, cites upcoming data for lead drug
|
Mar 1 |
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript
|
Mar 1 |
Crinetics Pharmaceuticals Full Year 2023 Earnings: Misses Expectations
|